Eyepoint Pharmac Stock Price, News & Analysis

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that CEO Nancy Lurker will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 10:30 a.m. ET. This presentation will highlight the company's commitment to developing innovative therapeutics for serious eye disorders. Investors can access a live webcast and an archived replay through the company website for 90 days post-event. EyePoint's pipeline includes EYP-1901, targeting wet age-related macular degeneration, utilizing its Durasert® technology for sustained drug delivery.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call scheduled for March 3, 2022, at 8:30 a.m. ET, to discuss its Q4 and full-year 2021 financial results and corporate developments. Interested participants can join by calling (877) 312-7507 domestically or (631) 813-4828 internationally, using conference ID 5058194. This presentation will also be available via live audio webcast on the company's website, with a replay accessible post-event. EyePoint is focused on therapeutics to treat serious eye disorders, leveraging its Durasert® technology.

EyePoint Pharmaceuticals (EYPT) announced positive interim data from the Phase 1 DAVIO clinical trial of EYP-1901, an intravitreal anti-VEGF treatment for wet age-related macular degeneration (AMD). The results, presented by Dr. Jay Duker, indicate a strong safety profile with no serious adverse events reported. After eight months, 41% of patients did not need supplemental anti-VEGF injections, showcasing a significant 75% reduction in treatment burden. A Phase 2 trial is anticipated in Q3 2022, following FDA discussions.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has released updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD, demonstrating positive safety and efficacy over eight months. A Phase 2 study is set to begin in Q3 2022 following a productive meeting with the FDA. In Q4 2021, customer demand for YUTIQ® and DEXYCU® surged by 16% and 5%, with cash reserves of approximately $210 million. Additionally, the company appointed Michael C. Pine as Chief Corporate Development and Strategy Officer, reinforcing its leadership as it pivots to retina-focused treatments.

EyePoint Pharmaceuticals, a leader in therapeutics for serious eye disorders, has appointed Michael C. Pine as Chief Corporate Development and Strategy Officer. Pine brings over 20 years of experience in the pharmaceutical sector, previously holding senior roles at Medexus, Lupin, Aralez, and Novartis. His expertise is expected to enhance EyePoint's corporate growth and strategic initiatives, particularly in advancing their product pipeline. In relation to Pine's appointment, 100,000 stock options were granted as part of his inducement award, adhering to Nasdaq guidelines.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced an expanded partnership with ImprimisRx for the U.S. sales and marketing of DEXYCU®, effective January 1, 2022. ImprimisRx will absorb most of EyePoint’s DEXYCU commercial organization, enhancing its ability to promote the injectable steroid treatment for post-operative inflammation. EyePoint retains revenue recognition, manufacturing, and distribution responsibilities. The partnership aims to accelerate DEXYCU’s growth and improve treatment accessibility for patients in need.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the closing of a public offering of 5,122,273 shares of common stock, including 1,095,000 shares purchased under the underwriter's option. The shares were priced at $13.75 each, with pre-funded warrants sold for $13.74 each, generating gross proceeds of approximately $115.4 million. The proceeds will support the Phase 2 clinical trials of EYP-1901 for wet AMD, DR, and RVO, along with earlier-stage pipeline initiatives. The offering was made under an SEC shelf registration statement.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced an underwritten public offering of 4,027,273 shares at $13.75 each, alongside pre-funded warrants for 3,272,727 shares at $13.74 each, aiming for gross proceeds of approximately $100.3 million. The funds will primarily advance EYP-1901 into Phase 2 trials for wet AMD, DR, and RVO, and support pipeline initiatives. The offering is expected to close by November 19, 2021, pending customary conditions.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced an underwritten public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million. The offering aims to fund Phase 2 clinical trials for EYP-1901, targeting wet AMD, diabetic retinopathy, and retinal vein occlusion. The proceeds will also support earlier stage pipeline initiatives and general corporate purposes. The securities are offered under a previously filed registration statement, and the offering's completion is subject to market conditions.